Search
Contact
04.12.2024 | Deal Notifications

KPMG Law and KPMG advises Brain Biotech AG on license agreements and monetization of license rights

KPMG Law Rechtsanwaltsgesellschaft mbH and KPMG AG Wirtschaftsprüfungsgesellschaft (KPMG) advised Brain Biotech AG on the monetization of licensing rights with Royalty Pharma and the conclusion of an exclusive pharmaceutical licensing agreement for the G-dase-E®-CRISPR-Cas technology with Akribion Therapeutics.

BRAIN Biotech has entered into an agreement with Royalty Pharma for the monetization of the license rights to the investigational pharmaceutical compound deucrictibant in the amount of up to EUR 128.88 million. BRAIN Biotech will receive an upfront payment of EUR 18.41 million, additional potential regulatory milestone payments of up to EUR 18.42 million and additional potential long-term sales-related milestones of up to EUR 92.05 million. In addition, BRAIN Biotech has entered into an exclusive technology license agreement with Akribion Therapeutics GmbH for the use of the genome editing nuclease G-dase E® for the pharmaceutical sector. BRAIN Biotech will receive up to EUR 92.3 million in R&D and commercial milestone payments from Akribion for the granting of these exclusive rights for use in the pharmaceutical field. In addition, BRAIN Biotech will be entitled to royalties from future net sales. The payment structure is based on progress in clinical development and future commercialization success. KPMG Law provided comprehensive legal advice on the structuring of the transaction, including all aspects of copyright, licensing and transaction law. The accounting and tax advice as well as the comprehensive valuation of the licenses was provided by a KPMG team. Royalty Pharma was advised by an international team from Goodwin Procter. Advisor Brain Biotech AG:

KPMG Law Rechtsanwaltsgesellschaft mbH: Stefan Kimmel (Partner, Corporate/M&A, Berlin), Dr. Anna Wipper (Partner, IP/IT, Berlin) – both lead – Gunars Urdze (Senior Manager, Corporate, M&A, Cologne), Dr. Thomas Beyer (Senior Manager, IP/IT, Berlin), Isabelle Knoché (Senior Manager, Legal Financial Services, Frankfurt/Main), Christina Laux (Senior Associate , Legal Financial Services, Frankfurt/Main),; Dr. Jonas Brueckner (Partner, Antitrust and Foreign Trade Law, Berlin).

KPMG AG Wirtschaftsprüfungsgesellschaft: Christian Klingbeil (Partner, Valuation, Head of Deal Advisory Life Science, Munich), Sebastian Bongartz (Senior Manager, International Transaction Tax, Düsseldorf).

 

Explore #more

05.01.2026 | In the media

KPMG Law expert in the Börsen-Zeitung on the digital euro

The digital euro is set to arrive by 2029. However, the central bank still has a lot of convincing to do. There is a great…

22.12.2025 | KPMG Law Insights

New EU directive tightens environmental criminal law

Environmental crime will be punished more severely in future. Directive (EU) 2024/1203 on the protection of the environment through criminal law is being transposed into…

19.12.2025 | KPMG Law Insights

Digital Omnibus: More efficiency instead of deregulation

The EU Commission wants to streamline digital laws. On November 19, 2025, it presented its proposals for the “Digital Omnibus” (including a separate AI Omnibus).…

18.12.2025 | Deal Notifications

KPMG Law and KPMG advise the shareholders of Frerk Aggregatebau on the sale to DEUTZ

KPMG Law Rechtsanwaltsgesellschaft mbH (KPMG Law) and KPMG AG Wirtschaftsprüfungsgesellschaft (KPMG) provided comprehensive advice to the shareholders of Frerk Aggregatebau GmbH (Frerk) on the sale…

17.12.2025 | KPMG Law Insights

AI-supported risk checks of NDAs and CoCs: how legal departments benefit

Artificial intelligence can relieve legal departments of routine tasks such as checking non-disclosure agreements (NDAs) or codes of conduct (CoCs). These documents are part of…

16.12.2025 | In the media

Interview with KPMG Law experts: CSDDD after the omnibus: “Toothless tiger” or pragmatic solution?

The agreement on the Omnibus I package is causing discussion. Among other things, the thresholds for the EU Supply Chain Directive (CSDDD) have been significantly…

15.12.2025 | In the media

KPMG Law guest article in Tagesspiegel Background: What the digital omnibus means for companies today

The debate on the digital omnibus has only just begun. Companies should contribute their expertise to the ongoing process and strengthen their internal foundations –…

12.12.2025 | KPMG Law Insights

Focus offshore: NRW buys extensive tax data on international tax havens

According to recent press reports from December 11, 2025, the state of North Rhine-Westphalia has purchased an extensive data set with tax-relevant information from international…

12.12.2025 | KPMG Law Insights

Legal changes in 2026: New obligations and relief for companies

Rarely has the new year been as difficult for companies to plan as 2026. All the signs in the EU are currently pointing towards reducing…

12.12.2025 | Deal Notifications

KPMG Law advises The Chemours Company on the implementation and closing of a large-volume factoring financing

KPMG Law Rechtsanwaltsgesellschaft GmbH (KPMG Law) advised the US-American Chemours Company on the implementation of a cross-border factoring financing. The legal implementation was managed by…

© 2024 KPMG Law Rechtsanwaltsgesellschaft mbH, associated with KPMG AG Wirtschaftsprüfungsgesellschaft, a public limited company under German law and a member of the global KPMG organisation of independent member firms affiliated with KPMG International Limited, a Private English Company Limited by Guarantee. All rights reserved. For more details on the structure of KPMG’s global organisation, please visit https://home.kpmg/governance.

 KPMG International does not provide services to clients. No member firm is authorised to bind or contract KPMG International or any other member firm to any third party, just as KPMG International is not authorised to bind or contract any other member firm.

Scroll